Solifenacin Succinate
Brand names: Solifenacin Succinate, Vesicare Ls, Vesicare
At a glance
- Medicare prescriptions, 2024
- 1,021,617
- Medicare drug cost
- $47.9M
- Average cost per prescription
- $46.89
- Clinicians who prescribed it
- 30,027
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 31.3%
- Family Medicine 17.9%
- Nurse Practitioners 16.4%
- Internal Medicine 14.9%
- Physician Assistants 10.5%
- Urogynecology 3.1%
- OB-GYN (Obstetrics & Gynecology) 2.5%
- Geriatric Medicine 1.0%
- General Practice 0.5%
- Neurology 0.3%
- Hospitalist 0.2%
- Nephrology (Kidney) 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 25% from 2019 to 2024.
Biggest change by state since 2019
- Louisiana +74%
- Arizona +68%
- Colorado +66%
- Minnesota +65%
- Alabama +65%
- New Hampshire (smallest change) −22%
- California (smallest change) −21%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bostal LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow round tablet, 6 mm | AP28 |
| 10 mg | yellow round tablet, 8 mm | AP29 |
Carilion Materials Management
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow round tablet, 8 mm | 150 |
Hec Pharm USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | white round tablet, 6 mm | C2 |
| 10 mg | white round tablet, 8 mm | C77 |
Macleods Pharmaceuticals Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | yellow round tablet, 6 mm | L22 |
| 10 mg | pink round tablet, 7 mm | L27 |
Proficient Rx LP
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | pink round tablet, 8 mm | U 329 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $959 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Astellas Pharma US Inc $959
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.